- Home
- ARR vs IMCR Comparison
ARR vs IMCR Comparison
Compare ARR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- IMCR
- Stock Information
- Founded
- ARR 2008
- IMCR 2008
- Country
- ARR United States
- IMCR United Kingdom
- Employees
- ARR N/A
- IMCR N/A
- Industry
- ARR Real Estate Investment Trusts
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARR Real Estate
- IMCR Health Care
- Exchange
- ARR Nasdaq
- IMCR Nasdaq
- Market Cap
- ARR 1.4B
- IMCR 1.5B
- IPO Year
- ARR N/A
- IMCR 2021
- Fundamental
- Price
- ARR $16.21
- IMCR $36.60
- Analyst Decision
- ARR Hold
- IMCR Buy
- Analyst Count
- ARR 5
- IMCR 10
- Target Price
- ARR $21.00
- IMCR $58.13
- AVG Volume (30 Days)
- ARR 2.3M
- IMCR 440.3K
- Earning Date
- ARR 07-23-2025
- IMCR 05-07-2025
- Dividend Yield
- ARR 17.77%
- IMCR N/A
- EPS Growth
- ARR N/A
- IMCR N/A
- EPS
- ARR N/A
- IMCR N/A
- Revenue
- ARR $44,778,000.00
- IMCR $333,581,000.00
- Revenue This Year
- ARR $532.77
- IMCR $25.96
- Revenue Next Year
- ARR $15.62
- IMCR $8.06
- P/E Ratio
- ARR N/A
- IMCR N/A
- Revenue Growth
- ARR 41.14
- IMCR 25.75
- 52 Week Low
- ARR $13.18
- IMCR $23.15
- 52 Week High
- ARR $21.93
- IMCR $49.05
- Technical
- Relative Strength Index (RSI)
- ARR 48.11
- IMCR 71.46
- Support Level
- ARR $15.61
- IMCR $31.14
- Resistance Level
- ARR $16.88
- IMCR $33.30
- Average True Range (ATR)
- ARR 0.30
- IMCR 1.94
- MACD
- ARR -0.05
- IMCR 0.57
- Stochastic Oscillator
- ARR 36.06
- IMCR 96.12
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.